Author/Editor		Nyssen, Olga P.; Bordin, Dmitry S.; Tepeš, Bojan; Perez -Aisa, Angeles; Vaira, Dino; Caldas, Maria; Bujanda Fernández de Piérola, Luis; Castro-Fernandez, Manuel; Lerang, Frode; Leja, Marcis; Rodrigo Sáez, Luis; Rokkas, Theodoros; Kupcinskas, Limas; Pérez Lasala, Jorge; Jonaitis, Laimas; Shvets, Oleg; Gasbarrini, Antonio; Simsek, Halis; Axon, Anthony T R; Buźas, György; Machado, Jose Carlos; Niv, Yaron; Boyanova, Lyudmila; Goldis, Adrian; Lamy, Vincent; Tonkić, Ante; Przytulski, Krzysztof; Beglinger, Christoph; Venerito, Marino; Bytzer, Peter; Capelle, Lisette; Milosavljević, Tomica; Milivojevič, Vladimir; Veijola, Lea; Molina-Infante, Javier; Vologzhanina, Liudmila; Fadeenko, Galina; Ariño, Inés; Fiorini, Giulia; Garre, Ana; Garrido, Jesús; Pérez, Cristina F.; Puig, Ignasi; Heluwaert, Frederic; Megraud, Francis; O'Morain, Colm; Gisbert, Javier P.
Title		European registry on Helicobacter pylori management (Hp-EuReg)
Type		članek
Vol. and No.		Letnik 70, št. 1
Publication year		2021
Volume		str. 40-54
ISSN		1468-3288 - Gut
Language		eng
Abstract		Objective The best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care. Design International multicentre prospective noninterventional registry starting in 2013 aimed to evaluate the decisions and outcomes in H. pylori management by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap. Variables included demographics, previous eradication attempts, prescribed treatment, adverse events and outcomes. Data monitoring was performed to ensure data quality. Timetrend and geographical analyses were performed. Results 30 394 patients from 27 European countries were evaluated and 21 533 (78%) firstline empirical H. pylori treatments were included for analysis. Pretreatment resistance rates were 23% to clarithromycin, 32% to metronidazole and 13% to both. Triple therapy with amoxicillin and clarithromycin was most commonly prescribed (39%), achieving 81.5% modified intention-to-treat eradication rate. Over 90% eradication was obtained only with 10-day bismuth quadruple or 14-day concomitant treatments. Longer treatment duration, higher acid inhibition and compliance were associated with higher eradication rates. Time-trend analysis showed a region-dependent shift in prescriptions including abandoning triple therapies, using higher acid-inhibition and longer treatments, which was associated with an overall effectiveness increase (84%-90%). Conclusion Management of H. pylori infection by European gastroenterologists is heterogeneous
Keywords		bolezni prebavil Helicobacter pylori